# Cancer-Related Fatigue

## Introduction

**Cancer-related fatigue (CRF)** is the most common symptom reported by cancer patients, affecting 60-90% during treatment and persisting in 30-40% of survivors for years after treatment completion. It is defined as a distressing, persistent sense of physical, emotional, or cognitive tiredness related to cancer or its treatment that is not proportional to recent activity and interferes with usual functioning.

## Pathophysiology

### Multifactorial Mechanisms
**Proinflammatory cytokine dysregulation** (IL-1, IL-6, TNF-alpha). Hypothalamic-pituitary-adrenal (HPA) axis disruption. Circadian rhythm disturbance and melatonin dysregulation. Skeletal muscle wasting and mitochondrial dysfunction.

Anemia and reduced oxygen-carrying capacity. Autonomic nervous system dysfunction. Central neurotransmitter changes (serotonin, dopamine).

### Contributing Factors
Cancer treatment effects (chemotherapy, radiation, immunotherapy, surgery). **Comorbid conditions**: Anemia, thyroid dysfunction, depression, pain, sleep disorders. Nutritional deficiency and cachexia. Deconditioning from reduced physical activity. Medications (opioids, antiemetics, sedatives). Psychosocial distress.

## Screening and Assessment

### Screening Tools
**Single-item screening**: "Rate your fatigue 0-10 over past 7 days". Mild: 1-3; Moderate: 4-6; Severe: 7-10. NCCN recommends screening at every visit during and after treatment. Threshold for comprehensive evaluation: score 4 or greater.

### Comprehensive Assessment Tools
**Brief Fatigue Inventory (BFI)**: 9 items; validated in cancer populations. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Multidimensional Fatigue Inventory (MFI). Cancer Fatigue Scale (CFS). Piper Fatigue Scale.

### Reversible Causes Workup
Complete blood count (anemia: Hgb <10 g/dL). Thyroid function tests. Electrolytes, renal and hepatic function. Vitamin D, B12, iron studies. Depression and anxiety screening (PHQ-9, GAD-7). Sleep quality assessment. Medication review. Pain assessment. ![Cancer-related fatigue screening and assessment algorithm](images/crf-screening-algorithm.jpg)

## Management

### Exercise (First-Line Intervention)
**Most effective intervention** for CRF with Level 1A evidence. Reduces fatigue by 40-50% during and after treatment. Aerobic exercise: 150 minutes/week moderate intensity (walking, cycling). Resistance training: 2-3 sessions/week.

Combination programs most effective. Safe during active treatment with appropriate precautions. Graded exercise approach with gradual progression.

### Psychosocial Interventions
**Cognitive behavioral therapy (CBT)**: Strong evidence for CRF. Psychoeducation on energy management. Stress reduction and coping strategies. Mindfulness-based stress reduction (MBSR). Support groups and peer counseling.

### Energy Conservation
**Activity pacing and prioritization**. Delegate non-essential tasks. Plan activities during peak energy periods. Structured rest periods (avoid prolonged bed rest). Ergonomic modifications at home and work. Occupational therapy for adaptive strategies.

### Pharmacological Interventions
**Methylphenidate**: Most studied psychostimulant; modest benefit. Modafinil/armodafinil: Mixed evidence; may help with severe fatigue. Corticosteroids (dexamethasone, methylprednisolone): Short-term benefit in advanced cancer. Treat reversible causes: Erythropoiesis-stimulating agents for chemotherapy-related anemia, thyroid replacement, antidepressants for comorbid depression. American ginseng: Some evidence in RCTs.

### Nutritional Interventions
Adequate caloric and protein intake. Correct nutritional deficiencies (vitamin D, iron, B12). Hydration management. Anti-inflammatory dietary patterns. Referral to oncology dietitian. ![Multimodal management approach for cancer-related fatigue](images/crf-management-approach.jpg)

## Special Considerations

### During Active Treatment
Fatigue typically peaks 2-3 days after chemotherapy. Cumulative worsening over treatment cycles. Exercise adherence may require modification of intensity. Balance rest and activity; avoid prolonged inactivity.

### Cancer Survivors
CRF persists in **30-40%** for months to years post-treatment. Screen for late effects contributing to fatigue. Structured exercise programs for survivors. Return-to-work planning with gradual reintegration. Address cancer-related cognitive impairment ("chemobrain").

### Palliative Setting
Corticosteroids for short-term energy improvement. Psychostimulants when appropriate. Focus on meaningful activity participation. Balance quality of life with symptom management. Caregiver education and support.

## Outcomes Measurement

Track fatigue scores longitudinally. Functional measures: 6MWT, grip strength, TUG. Quality of life outcomes: FACT-G, EORTC QLQ-C30. Return to work and role function. Physical activity levels (accelerometry, activity logs).

![Exercise prescription guidelines for managing cancer-related fatigue across treatment phases](images/crf-exercise-guidelines.jpg)

## Key Clinical Pearls

1. **Exercise is the most effective intervention** for cancer-related fatigue, with stronger evidence than any pharmacological agent, and is safe during active treatment. 2. Screen for reversible contributing factors (anemia, thyroid dysfunction, depression, sleep disorders, vitamin deficiencies) before attributing fatigue solely to cancer or treatment. 3. Fatigue screening should be performed at every oncology visit using a simple 0-10 scale, with scores of 4 or greater triggering comprehensive evaluation. 4. Energy conservation and activity pacing are essential self-management strategies but should not replace structured exercise programs.

## References

1. Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. *Journal of Clinical Oncology*. 2014;32(17):1840-1850.
2. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. *JAMA Oncology*. 2017;3(7):961-968.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-related fatigue. Version 2.2024.
4. Berger AM, Mooney K, Alvarez-Perez A, et al. Cancer-related fatigue, version 2.2015. *Journal of the National Comprehensive Cancer Network*. 2015;13(8):1012-1039.